Tumour necrosis factor‐alpha, interleukin‐10, interferon‐gamma and vitamin D receptor gene polymorphisms in patients with chronic hepatitis delta. Issue 4 (22nd July 2013)

• Record Type: Journal Article
• Authors: Karatayli, S. C.; Ulger, Z. E.; Ergul, A. A.; Keskin, O.; Karatayli, E.; Albayrak, R.; Ozkan, M.; Idilman, R.; Yalcin, K.; Bozkaya, H.; Uzunalimoğlu, O.; Yurdaydin, C.; Bozdayi, A. M.
• Is Part Of: Journal of viral hepatitis. Volume 21:Issue 4(2014)
• Page Start: 297
• Page End: 304
• Publication Date: 2013-07-22
• Subjects: Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.12139
• Languages: English
• ISSNs: 1352-0504

Abstract

<abstract abstract-type="main" id="jvh12139-abs-0001"> <title>Summary</title> <p>No data exist to assess certain polymorphisms that have a potential effect on the immune response in patients with chronic hepatitis delta (CHD). The aim of this study was to investigate polymorphisms in 6 polymorphic sites: IL‐10 ‐1082 (rs1800896), IL‐10 ‐627 (rs1800872), IFN‐γ +874 (rs62559044), TNF‐α ‐308 (rs1800629), vitamin D receptor (VDR) <italic>Fok</italic>I (rs2228570) and VDR <italic>Taq</italic>I (rs731236). The genotypes of 67 patients with CHD and 119 patients with chronic hepatitis B (CHB) were compared. In addition, 56 individuals with resolved hepatitis B virus (HBV) infection were used as a control group for patients with CHB. Polymorphisms in TNF‐α, IL‐10, and VDR genes were analysed using polymerase chain reaction/restriction fragment length polymorphism methods. The IFN‐γ gene polymorphism was detected by allele‐specific polymerase chain reaction (PCR). Patients with CDH were more likely to have advanced liver disease compared with patients with CHB (<italic>P</italic> < 0.0001). IL‐10 ‐1082 and VDR <italic>Taq</italic>I polymorphisms showed significant differences between patients with CHD and CHB. The high secretory IL‐10 ‐1082 genotype GG was less frequent in CHD compared with patients with CHB and resolved HBV (17.7%, 37.4% and 47.1%, respectively (<italic>P</italic> < 0.05 for CHD <italic>vs </italic>CHB and resolved HBV). The frequency of the high secretory VDR <italic>Taq</italic>I TT genotype was 86.6% in patients with CHD, 62.7% in patients with CHB and 62.5% in resolved HBV individuals (CHD <italic>vs </italic>CHB:<italic> P</italic> < 0.05). None of the polymorphisms analysed had an effect on HBV persistence. IL‐10 ‐1082 and VDR <italic>Taq</italic>I polymorphisms may contribute to the more severe liver disease associated with CHD compared with CHB.</p> </abstract>